RT Journal Article
SR Electronic
T1 Histological typing of lung cancer in bioptically obtained specimens under the aspect of therapeutical approaches – A multi-center study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4674
VO 38
IS Suppl 55
A1 Annette Fisseler-Eckhoff
A1 Rica Zinsky
A1 Florian Laenger
A1 Phillip Schnabel
A1 Iver Petersen
A1 Klaus Junker
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/4674.abstract
AB The insufficiency of classifing lung cancer as SCLC or NSCLC clinical arose with the approval of the antifolate pemetrexed, which has a lower antitumorous effectivity in Squamous Cell Carcinoma. Often only biopsy specimens are available to exclude a squamous differentiation before chemotherapy decision.The restrictive nature of subtyping lung cancer in biopsies demanded a skilled and experienced pathologist. This interlaboratory comparison should discover the accordance of subtyping of lung cancer biopsies evaluated in 5 different pathological institutes in germany. Is it possible to improve the accuracy histological typing by additional immunhistochemistry (IHC) panel?60 biopsy specimens with Hematoxylin-eosin (HE) stain and immunhistological stained slides of at least Ck7, Ck5/6, p63, TTF1 were assembled and analysed from the pathologists. An estimation of predominantly-non-squamous yes/no and the histological subtype was done after examination the HE slide and again after the examination of the IHC. These two results were compared.All 60 cases were analysed by all 5 participants. In average the agreement of predominantly-non-squamous with inspecting the HE slide was 50% and arose after IHC to 87%. The accordance of histological subtype arose from 58% after HE slide to 88% after IHC.Histological subtyping of lung cancer biopsies can be done reliably with the help of an immunhistochemical panel of CK5/6, CK7, TTF1 and p63. Thus, we recommend the use of IHC to ensure diagnosis of lung cancer biopsies especially for patients coming into consideration for pemetrexed chemotherapy.